• Cleavage-Resistant TREM2 Restores Macrophage Efferocytosis

  2026-10-08

  Dong et al. report a synthetic cleavage-resistant TREM2 receptor that preserves macrophage efferocytosis despite inflammatory ADAM17 activity. Delivered as mRNA through phosphatidylserine-functionalized lipid nanoparticles, the receptor reduced apoptotic-cell accumulation and inflammation in mouse models of metabolic-dysfunction-associated steatohepatitis and atherosclerosis.

• 293T Cells in Multiplexed CRISPR Research

  2026-10-08

  293T Cells provide a useful human-cell context for interpreting multiplexed CRISPR findings, but they should not be treated as universal proxies for primary tissues or therapeutic models. This article explains how cell state, structural variation, DNA-damage burden, and endpoint selection shape the strength of genome-engineering evidence.

• TRIM21–ERK1/2 Signaling in Pituitary Adenomas

  2026-10-07

  The 2025 Neuro-Oncology study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and dopamine-agonist resistance. Its integrated genetic, biochemical, animal, and drug-screening evidence nominates TRIM21 as a research target while showing that Quisinostat-associated effects require further mechanistic and translational validation.

• 10 mM dNTP Mixture as an Assay Control

  2026-10-07

  Explore how the 10 mM dNTP mixture functions as a defined DNA synthesis reagent and an important control variable in molecular biology. This article connects nucleotide composition with the interpretation of nucleic-acid delivery studies while clearly separating reagent effects from cellular trafficking biology.

• eIF4F–AKT1–EZH2 Inhibition in BRAFV600E Melanoma

  2026-10-06

  The reference study identifies coordinated ERK1/2–EZH2 and AKT1–eIF4E signaling as a mechanism by which BRAFV600E melanoma cells resist eIF4F-complex and BRAF inhibition. Its main innovation is the use of combined eIF4F, EZH2, and AKT1 blockade to improve suppression of resistant melanoma models, while also showing that resistance-associated signaling is temporally distinct and mechanistically interconnected.

• Polygodial and TRPA1 Channel Activation

  2026-10-06

  Polygodial is a research compound described as a TRPA1 channel activator. The available 2024 study supports a TRPA1-linked calcium/NFAT pathway in nasal epithelial cells, but it does not establish that polygodial itself produced those reported epithelial outcomes.

• Entecavir and HBV Resistance: Reading the Evidence

  2026-10-05

  Entecavir is a potent HBV polymerase inhibitor, but resistance risk depends strongly on prior nucleos(t)ide exposure. This evidence-focused analysis explains what the 2024 meta-analysis reveals, where its estimates are robust, and where clinical and surveillance gaps remain.

• LNP mRNA Vaccine Design for RSV: Study Findings

  2026-10-05

  A 2025 Journal of Pharmaceutical Investigation study developed and evaluated a lipid nanoparticle system for intramuscular delivery of mRNA encoding a conserved region of the RSV G glycoprotein. The preclinical formulation showed strong expression, antibody and T-cell responses, and complete protection in the reported RSV challenge model, while its relevance beyond this antigen, formulation, and animal setting remains to be established.

• Sulfachloropyridazine in E. tenella Cecal Omics

  2026-10-04

  The 2022 Microbial Pathogenesis study combined 16S rRNA gene sequencing with LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment reshape the chicken cecal environment. Its findings distinguish an ethanamizuril-associated microbiota profile, reduced Escherichia-Shigella after sulfachlorpyridazine treatment, and comparatively limited effects from the low-dose combination, while emphasizing that these are context-specific associations rather than proof of mechanism.

• Isorhamnetin: PI3K/Akt Evidence Guide

  2026-10-03

  Isorhamnetin is a flavonoid compound linked to PI3K/Akt activation in a preclinical porcine oocyte study. The evidence supports research into oxidative stress, apoptosis, mitochondrial regulation, and endoplasmic reticulum stress, but it does not establish human fertility efficacy or a universal pathway effect.

• 293T Cells for CRISPR Workflow Design

  2026-10-02

  293T Cells provide a human cell-based platform for transient expression, reporter testing, and genome-engineering workflows, but the cells do not perform CRISPR editing without externally supplied editing components. Their biological rationale derives from the HEK293 lineage and SV40 large T-antigen expression, while multiplex CRISPR applications require independent guide, nuclease, and control design.

• Dutasteride Workflows for Prostate Research

  2026-10-01

  Dutasteride supports mechanism-driven studies that connect dual 5-alpha-reductase inhibition with DHT depletion, growth control, and apoptosis readouts. This workflow emphasizes solvent discipline, orthogonal target-engagement assays, and a carefully bounded comparison with metabolite–immune signaling research.

• 7-AAD Cell Viability Assay Kit for CAR-T Readouts

  2026-10-01

  The 7-AAD Cell Viability Assay Kit provides a red-fluorescence membrane-integrity readout for necrotic and late apoptotic cells. Its compatibility with flow cytometry, fluorescence microscopy, and multiplex markers makes the 7-amino actinomycin D assay useful for evaluating cytotoxicity and fratricide in CD38 CAR-T research.

• Resiquimod (R-848) for Ablation Immunotherapy

  2026-09-30

  Resiquimod (R-848) connects TLR7/8 activation with practical assays for cytokine release, dendritic-cell maturation, macrophage polarization, and localized tumor-ablative immunotherapy. This guide translates a thermal-protective hydrogel study into controlled workflows that distinguish compound activity from heat injury, formulation effects, and delivery kinetics.

• HyperScribe™ Cy5 RNA Labeling Kit: Lab Guide

  2026-09-30

  Learn how SKU K1062 can support reproducible fluorescent RNA probe synthesis when viability, proliferation, or cytotoxicity assays require mechanistic transcript-level context. This scenario-based guide covers probe design, T7 transcription, Cy5-UTP optimization, interpretation, and practical product selection.

8592 records 1/573 page Next 12345 下5页 Last page